Update in primary pulmonary lymphomas

Jose Cardenas-Garcia, Arunabh Talwar, Rakesh Shah, Alan Fein

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Purpose of review Despite the fact that primary pulmonary lymphoma (PPL) is a rare lung tumour, significant advances addressing clinical features, histological diagnosis, prognostic criteria and therapeutic management of this disease have been made within the past decade. Recent findings Monoclonality and phenotyping of alveolar lymphocytes are suggestive of mucosa-Associated lymphoid tissue (MALT). Detection of MALT-1 gene rearrangements in bronchoalveolar fluid cells using fluorescence in-situ hybridization techniques helps to confirm the diagnosis of MALT PPL. Fine needle aspirationcomputed tomography guided biopsies as well as transbronchial/cryobiopsies provide adequate tissue material for histological evaluation. Recent publications also provide a better appreciation of newer chemotherapeutic approaches, including fludarabine and mitoxantrone with or without ritubximab for the treatment of MALT, as well as complete surgical resection if local disease is present. Prognostic factors influencing survival and optimal therapy for MALT have not been well defined, but the use of tumour microvascular density appears promising. Summary This review outlines the implications of recent findings for clinical practice and research progress of PPL. Larger, multicentre and well designed studies are imperative to optimize the current diagnostic and therapeutic approach for this disease.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalCurrent opinion in pulmonary medicine
Issue number4
StatePublished - Jul 1 2015

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Update in primary pulmonary lymphomas'. Together they form a unique fingerprint.

Cite this